Company / SG&A Expense
LeMaitre Vascular SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$42.0M
FY2025
5-year range
$19.1M / $42.0M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
#149 of 158
Health Care
What the data says
Among 158 Health Care companies, LeMaitre Vascular is in the top 6% for sg&a expense. SG&A Expense has increased for 8 consecutive years, from $14M in FY2017 to $42M in FY2025.
Based on SEC 10-K filings.
$42M in FY2025 with a 5-year CAGR of +18.9%.
Increased from $32M to $42M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +23.1%
- 5-Year CAGR
- +18.9%
- 10-Year CAGR
- -
Sector benchmark
Top 6% in Health CareTop 6% of 158This company $42.0M Sector average $175.9B
▼
-100.0% below sector average
Key checks
Key Insights
- LeMaitre Vascular's sg&a expense has grown for 8 consecutive years.
- 5-year CAGR of +18.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 15.9% year-over-year.
- Ranks #149 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 20.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $42.0M | +15.9% |
| FY2024 | $36.3M | +13.9% |
| FY2023 | $31.8M | +41.5% |
| FY2022 | $22.5M | +18.1% |
| FY2021 | $19.1M | +7.7% |
| FY2020 | $17.7M | +4.0% |
| FY2019 | $17.0M | +18.5% |
| FY2018 | $14.4M | +2.5% |
| FY2017 | $14.0M | -2.4% |
| FY2016 | $14.4M | +14.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026